Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: A remission induction therapy of granulocyte and monocyte adsorptive apheresis (GMA) was given to patients with Crohn's disease (CD). However, establishing an appropriate treatment strategy for GMA in patients with CD remains unclear.
Methods: This study evaluated the clinical efficacy and subsequent clinical progression after GMA in patients with CD who underwent GMA in seven independent institutions in Japan from 2010 to 2023.
Results: Sixteen patients were enrolled. The overall remission and response rates were 25.0% and 68.8%, respectively. All patients responding to GMA received biologics that were continuously used and 36.4% of patients remained on the same biologics 52 weeks after GMA. Notably, all patients who continued the same biologics had previously experienced a loss of response to biologics.
Conclusion: GMA may exhibit effectiveness even in cases with refractory CD. Moreover, it represents a potential novel therapeutic option for refractory CD with loss of response to biologics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1744-9987.14103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Randomized, Observer-Blinded, Active-Controlled, Phase IIIb Study to Compare IV/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections: The DRESS Study.
Open Forum Infect Dis
September 2025
Faculty of Medicine and Surgery, Catholic University of Sacred Heart, Rome, Italy.
Background: Surgical site infections (SSIs) are the most common skin and skin structure infections and are mostly polymicrobial, requiring hospitalization and broad-spectrum antibiotics. This clinical trial evaluated the noninferiority of delafloxacin vs best available therapy (BAT) for the treatment of superficial or deep incisional SSI following a cardiothoracic/related leg or abdominal surgical procedure.
Methods: In this randomized, observer-blinded, active-controlled, parallel-group, multicenter, phase IIIb study, patients with SSI were randomized 1:1 to receive delafloxacin 300 mg intravenous (IV)/450 mg oral (OS) or BAT IV/OS (vancomycin or linezolid for cardiothoracic SSI, piperacillin/tazobactam or tigecycline for abdominal SSI).
General practice is 'talking medicine' and communication is an essential part of every medical activity, and also influences key outcome parameters (e.g. adherence, healing success) and even job satisfaction of physicians.
View Article and Find Full Text PDFAssociation of Gene Variants with Severe COVID-19 Among Fully Vaccinated vs. Non-Vaccinated Individuals.
Life (Basel)
July 2025
Genética Molecular, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
The STING protein is activated by the second messenger cGAMP to promote the innate immune response against infections. Beyond this role, a chronically overactive STING signaling has been described in several disorders. Patients with severe COVID-19 exhibit a hyper-inflammatory response (the cytokine storm) that is in part mediated by the cGAS-STING pathway.
View Article and Find Full Text PDFCombining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models.
Cell Rep Med
August 2025
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. Electronic address:
Second mitochondrial activator of caspase (SMAC) mimetics (SMACm) and bromodomain and extra-terminal domain (BET) inhibitors (BETi) are two distinct classes of novel anticancer therapeutics. So far, broad clinical benefit for either monotherapy has not been achieved, calling for effective combination strategies. We show that the combination of BI 891065, a monovalent oral SMACm antagonist of inhibitor of apoptosis protein 1 (cellular inhibitor of apoptosis protein 1 [cIAP1]), and BI 894999, a potent and selective oral BETi, significantly impaired cancer cell proliferation irrespective of tissue context.
View Article and Find Full Text PDFA comparative 48 month randomized trial of clinical performance and wear of BISGMA based and BISGMA free nanoceramic resin composites.
Sci Rep
August 2025
Conservative Dentistry Department, Faculty of Dentistry, Cairo University, Giza, Egypt.
This study aimed to compare the 48-month clinical performance and wear of Bis-GMA-based and Bis-GMA-free nanoceramic resin composites in Class I posterior restorations. In a randomized clinical trial, 64 patients received occlusal restorations with either Zenit (Bis-GMA-based) or Neo Spectra ST (Bis-GMA-free) nanoceramic composites (n = 32). Clinical performance was evaluated using modified USPHS criteria at four timepoints (baseline, 12, 24, 48 months).
View Article and Find Full Text PDF